AI-Driven Inflation Raises U.S. Consumer Prices, Goldman Sachs Says 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
Medicare to Cover GLP-1 Weight-Loss and Diabetes Drugs Starting July 1 
How to support someone who is grieving: five research-backed strategies 
Dollar Gains on Safe-Haven Demand as Iran Tensions and Inflation Data Loom 
ECB Signals Possible Interest Rate Move if Inflation Outlook Fails to Improve 
The ghost of Robodebt – Federal Court rules billions of dollars in welfare debts must be recalculated 
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 
Gold Prices Slip as Strong Dollar and Rising Oil Weigh on Market Sentiment 
Trump Rejects Iran Proposal as Strait of Hormuz Crisis Pushes Oil Prices Higher 
6 simple questions to tell if a ‘finfluencer’ is more flash than cash 
US Auto Industry Urges Trump to Block Chinese EV Market Access 
CDC Monitors U.S. Travelers After Hantavirus Outbreak on Luxury Cruise Ship 
U.S. Officials Express Optimism Over New CDC Director Selection Amid Vaccine Policy Turmoil 
Heritage, desire and diplomacy: why China still values scotch whisky 
Coca-Cola Japan and Kirin Holdings will develop health drinks that contain the live bacteria, lactococcus lactis strain plasma (LC-Plasma), an ingredient patented by Kirin that is used in the company's health drinks.
Kirin claims that the live bacteria boosts immunity in healthy people.
Kirin is the first among companies that make foods and beverages they claim to boost immunity to have been approved by Japan's Consumer Affairs Agency in 2020 to advertise its products as such.
Coca-Cola Japan plans to put LC-Plasma into three of its brands, Georgia, Irohasu, and Minute Maid.
The Consumer Affairs Agency has also given the go-ahead for the drinks to be advertised as having the advantage.
The partnership demonstrates Coca-Cola Japan's intention to improve its position in the health beverage market. According to market research firm Inryo Soken, Coca-Cola has a 26 percent market share in soft drinks but has not advanced significantly in the market for health beverages.
On the other hand, Kirin is increasing sales of its LC-Plasma component and sees health products as its next area of growth. It anticipates that by 2027, sales of health drinks will have increased fivefold from their current level to 50 billion yen.
Taisho Pharmaceutical Holdings, as well as candy manufacturers including Morinaga & Co. and Kanro, have already purchased the component from Kirin.
Although supplying a rival with distinctive ingredients would negate Kirin's advantage, collaborating with Coca-Cola might let it expand its market.
